Galderma adds new indication for blockbuster hope Nemluvio Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to its label. R&D ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback